130 related articles for article (PubMed ID: 37686097)
1. Suppressing Src-Mediated EGFR Signaling by Sustained Calcium Supply Targeting Triple-Negative Breast Cancer.
Jeong KY; Park SY; Park MH; Kim HM
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686097
[TBL] [Abstract][Full Text] [Related]
2. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
[TBL] [Abstract][Full Text] [Related]
3. Potential Anticancer Effect of Calcium-mediated Src Degradation on Hormone-dependent Breast Cancer.
Park SY; Lee JK; Park MH; Jeong KY; Kim HM
Anticancer Res; 2020 Apr; 40(4):1989-1996. PubMed ID: 32234888
[TBL] [Abstract][Full Text] [Related]
4. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
[TBL] [Abstract][Full Text] [Related]
5. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
6. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
[TBL] [Abstract][Full Text] [Related]
8. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
Lou L; Yu Z; Wang Y; Wang S; Zhao Y
Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
McKnight BN; Kim S; Boerner JL; Viola NT
Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
[TBL] [Abstract][Full Text] [Related]
10. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin Mediated Degradation of EGFR by 17 β-estradiol in Triple Negative MDA-MB-231 (TNBC) Breast Cancer Cells Line.
Khode V; Patil S; Kaveeshwar V; Ruikar K; Bargale A; E S; Patil S
Curr Mol Med; 2022; 22(5):449-457. PubMed ID: 34376133
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
14. Antitumor Effect of Calcium-Mediated Destabilization of Epithelial Growth Factor Receptor on Non-Small Cell Lung Carcinoma.
Kim IU; Sung IS; Sim JJ; Park M; Jeong KY; Kim HM
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641465
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Gautam J; Banskota S; Lee H; Lee YJ; Jeon YH; Kim JA; Jeong BS
Exp Mol Med; 2018 Sep; 50(9):1-14. PubMed ID: 30185799
[TBL] [Abstract][Full Text] [Related]
16. All-trans-retinoic acid activates the pro-invasive Src-YAP-Interleukin 6 axis in triple-negative MDA-MB-231 breast cancer cells while cerivastatin reverses this action.
Mezquita B; Mezquita P; Pau M; Gasa L; Navarro L; Samitier M; Pons M; Mezquita C
Sci Rep; 2018 May; 8(1):7047. PubMed ID: 29728589
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
[TBL] [Abstract][Full Text] [Related]
18. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling.
Wang K; Zou P; Zhu X; Zhang T
Toxicol In Vitro; 2019 Dec; 61():104653. PubMed ID: 31525383
[TBL] [Abstract][Full Text] [Related]
19. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
20. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
Cheng W; Liu D; Guo M; Li H; Wang Q
Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
